CROs offering Specialized & Large-Animal Models with Biologics (Monoclonal Antibodies)

Matching companies

• Aragen Life Sciences

  Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.

• Axcelead Drug Discovery Partners, Inc.

  Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.

• BioDuro-Sundia

  BioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.

• Champions Oncology

  Leading oncology CRO specializing in preclinical and clinical specialty testing, with over 1,400 patient-derived xenograft models, comprehensive multi-omic datasets, and proprietary platforms including flow cytometry, NGS, proteomics, and histopathology services.

• ChemPartner

  Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.

• Creative Bioarray

  Creative Bioarray provides preclinical research solutions including drug screening, ADME-PK, toxicity studies, and cell-based services across oncology, neurology, cardiovascular, and metabolic therapeutic areas.

• Crown Bioscience

  Preclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.

• Cyagen Biosciences

  Cyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical research, with specialized expertise in humanized mice, gene therapy vectors, and disease-specific models across oncology, neurology, and metabolic disorders.

• Cyagen Biosciences

  Cyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical drug discovery, with specialized platforms including HUGO-GT™ and HUGO-Ab™ for humanized target validation and antibody screening.

• Frontage Laboratories

  Global pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.

• GemPharmatech

  GemPharmatech develops and supplies genetically engineered mouse models (GEMMs) and preclinical research services using CRISPR/Cas9 and gene-editing technologies, with a library of 25,000+ mouse strains including KO/cKO, humanized, and immunodeficient models.

• Labcorp

  Labcorp is a global life sciences and healthcare company providing diagnostic testing, drug development, nonclinical research, central laboratory services, and real-world data solutions to healthcare providers, health systems, and biopharma companies.

• PharmaLegacy Laboratories

  Preclinical CRO with over 1,500 validated in vivo efficacy models spanning 100+ indications in oncology, immunology, inflammation, and bone disease. AAALAC-accredited vivarium with capacity for 30,000 rodents and 350 non-human primates supports IND filings to FDA and CFDA.

• Protheragen

  Specialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.

• Reaction Biology

  Global preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.

• Syngene International

  Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

• WuXi AppTec

  Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.